A client with type 2 diabetes mellitus is managed with glimepiride. The primary healthcare provider (HCP) adds a new prescription for injectable glucagon-like peptide 1 (GLP-1) receptor agonist. Which information is most important for the nurse to teach this client?

A. Notify the healthcare provider if anorexia occurs: Mild anorexia can be a common side effect of GLP-1 receptor agonists due to delayed gastric emptying. While it should be reported if severe or persistent, it is not the most urgent safety concern. B. Consume additional sources of potassium: GLP-1 receptor agonists do not significantly impact potassium levels, so increasing potassium intake is not a routine teaching point. This instruction would be more relevant for medications affecting electrolyte balance. C. Watch for signs of jitteriness or diaphoresis: These are symptoms of hypoglycemia, which can occur when GLP-1 receptor agonists are combined with sulfonylureas like glimepiride. Teaching the client to recognize and promptly address these signs is critical to preventing severe hypoglycemic events. D. Administer subcutaneously after meals: GLP-1 receptor agonists are administered subcutaneously but are not specifically given after meals. Their dosing schedule depends on the formulation, with some given daily and others weekly, and meal timing is generally not a requirement.